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It is about 20 years since the first cord blood transplant (CBT) was performed in a young patient with Fanconi's anaemia. Since 
then, due to technological advances, there has 
being a tremendous progress in the utilisation and 
application of CBT, both in terms of quantity and 
quality.1
The use of CBT has  risen following the 
understanding that cord blood (CB), which is 
normally wasted following delivery of a baby, 
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اخلال�صة: مّر اأكرث من ع�رسين �ضنة على اأول زراعة من دم احلبل ال�رسي، وجاءت هذه العملية بعد التحقق من اأّن دم احلبل ال�رسي )الذي 
اإنتاج خليا الدم. ومنذ ذلك احلني مت  عادة ما كان ُيهدر( غني باخلليا الأ�ضلية )اجلذعية( التي ميكن ال�ضتفادة منها يف اإعادة منو 
التعرف على كثري من خ�ضائ�س دم احلبل ال�رسي، التي من �ضمنها قدرته على اإ�ضعاف املري�س املحتاج لزراعة هذا الدم دون احلاجة 
اإىل اأن يكون هناك تطابقا كامل مل�ضت�ضد اخلليا الليمفاوية. كذلك فاإن دم احلبل ال�رسي متوفر، ويكون خاليا من الكائنات املجهرية 
امل�ضببة للعدوى ن�ضبيا، كما اأنه ل ي�ضكل اأي خطر على ال�ضخ�س الذي اأخذ منه. غري اأن كمية دم احلبل ال�رسي قليلة ولذلك فاإن اإ�ضتخداماته 
حمدودة للأطفال اأو الكبار الذين هم بحاجة اإىل وحدتني معا. ويف ُعمان، كان هناك اهتمام كبري مبو�ضوع البحوث يف اخلليا اجلذعية 
اأو  وزراعة دم احلبل ال�رسي، وارتاأينا اأن مثل هذه الأن�ضطة متثل مدخل لكثري من املر�ضى الذين ل يتوفر لهم متربع للنخاع العظمي 
احلبل  لدم  التطوعي  الوطني  امل�رسف  تاأ�ضي�س  اإىل  �ضجعنا  ما  وهذا  لهم.  اآخر  ال�رسي خمرجا  احلبل  دم  ي�ضكل  وبالتايل  اخلارجي  للدم 
ال�رسي، والذي �ضيكون خيارا ممتازا لبع�س املر�ضى، بعك�س امل�رسف التجاري لدم احلبل ال�رسي الذي حتوم حوله ال�ضبهات. �ضيحوي هذا 
امل�رسف الوطني متطلبات املنطقة من التطابق لأنواع م�ضت�ضد اخلليا الليمفاوية و�ضيكون مفيدا لعتماده على م�ضارف م�ضابهة يف 
دول اأخرى. وبالنظر حلاجة البلد اإىل زراعة اخلليا اجلذعية والعلج بها فاإن اإن�ضاء م�رسف كهذا �ضوف يخدم بع�س املتطلبات الوطنية.
مفتاح الكلمات: دم احلبل ال�رسي، زراعة دم احلبل ال�رسي، اخلليا اجلذعية يف دم احلبل ال�رسي، جتميع دم احلبل ال�رسي، امل�رسف الوطني 
لدم احلبل ال�رسي، امل�رسف اخلا�س لدم احلبل ال�رسي، ُعمان.
abstract: It is more than 20 years since the first cord blood transplant (CBT) was performed, following the 
realisation that cord blood (CB), which is normally wasted, is rich in progenitor cells and capable of rescuing 
haematopoiesis. Since then it has been appreciated that CB is rich in stem cells, and has many other features not 
the least of which is its ability to rescue the transplanted patient without a rigid need for full human lymphocyte 
antigen (HLA) compatibility. Also it is easily accessible, relatively free from infections and poses no medical risk to 
the donor. However, the quantity of the stem cells is rather small, thus predominantly restricting its use to children 
or adults requiring double units. In Oman, we have taken a keen interest in stem cell research and also CBT. 
We see such activities as an avenue for our patients, for whom a compatible bone marrow (BM) or a peripheral 
blood donor cannot be found, to have an alternative in the form of CBT. This has encouraged us to establish a 
national voluntary cord blood bank (CBB) which is a valuable option open to a selected group of patients, as 
compared to the controversial private CBB. This national CBB will have a better representation of HLA-types 
common in the region, an improvement on relying on banks in other countries. Considering the need for stem 
cell transplant/therapy in this country, it is only appropriate that this sort of bank is established to cater for some 
of these requirements. 
Keywords: Umbilical cord blood; Cord blood transplantation; Cord blood stem cell; Cord blood banking; Private 
cord blood bank; National cord blood bank.
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contains large quantities of pluripotential stem 
cells that could be utilised to regenerate or rescue 
haematopoietic stem cells (HSC), following their 
exposure to accidental or therapeutic ablative 
therapy. Pleuripotent stem cells are undifferentiated 
cells that are capable of dividing, self-renewal, and 
generating progeny of highly specialised cells, upon 
exposure to optimal environmental stimuli in what 
is termed a bone marrow microenvironment.2,3 This 
microenvironment is under the influence of various 
biomolecules, with interplay between adhesions 
molecules, cytokines and their receptors.3 
The stem cells found in CB are also similar to 
those found in the bone marrow and are responsible 
for the regenerative capacity of the bone marrow’s 
haematopoietic activities. The initial experiments 
centered on a severe combined immune deficiency 
(SCID) mouse model that could be rescued by 
giving these stem cells. The progress that was 
made in this area was paralleled by progress in 
the ability to define these stem cells through the 
process of antibody labelling using flowcytometry, 
combining both functional and phenotypic assays.4 
More recently, the focus has also been on the 
stromal support cells as they are found to play 
a crucial role in maintaining the integrity of the 
haematopoietic cellular milieu.5 These cells 
originate from mesenchymal stem cells that are not 
only necessary for the integrity of other marrow 
stem cells, but are capable of giving rise to many 
tissue types including cartilage, fat, muscle and 
bones.5,6 Subsequently, it has been demonstrated 
that cord blood units (CBU) have a number of 
features which makes them a highly favourable 
source of stem cells in the ever expanding range of 
stem cell therapy. Having realised the potential uses 
of CBUs, it was deemed necessary to establish cord 
blood banks (CBBs) in order to collect and store 
these units until the need for them arose. 
Advantages of Cord Blood 
Transplants
A CBU contains a large number of progenitor cells 
that can be used to transplant most paediatric 
and some adult patients who require this form of 
therapy. These units have a low risk of viral infection 
(although this is not completely eliminated as 
Epstein-Barr virus [EBV] cases has been reported), 
in particular from cytomegalovirus [CMV].7 
Moreover, CBUs are accessible and secured, so that 
they could be used at any time. This means that CBU 
units are ready for use when the recipient is ready 
for them, and so the transplant can be scheduled at 
the convenience of the recipient (patient) and not 
that of the donor. Furthermore, it is also known that 
the incidence of graft-versus-host disease (GVHD) 
is lower compared with bone marrow or peripheral 
blood transplantation. This may be related to the 
immaturity of the immune system at birth and the 
decreased potential of alloreactive lymphocytes.8 
As a result, it is not strictly necessary to have a 
complete HLA match in CBU selection compared 
to peripheral blood or bone marrow selection. At 
the same time, the graft-versus-leukaemia (GVL) 
effect is maintained, fulfilling one of the main 
purposes of any allogeneic stem cell transplant 
procedure. Additional advantages, include zero risk 
to the donor since this blood is normally not used 
and wasted [Table1].
Disadvantages of Cord 
Blood Transplants
There are, however, some obstacles to the 
widespread use of CBU [Table 2], including the 
sometimes small number of stem cells in each 
unit, which leads to a delayed engraftment, and 
may be reflected in the increased transplant related 
mortality/morbidity and reduced survival. This is 
Table 1: Advantages of cord blood transplantation
Advantage Comments
Rich in progenitor cells Capable of durable 
engraftment and long-term 
haematopoiesis in adults 
and children 
Relatively free from 
infections 
Translates to reduced 
transplant mortality/ 
morbidity  
CBUs are accessible  Transplantation scheduled 
to recipient convenience 
GVHD is less Improved survival
GVL is maintained Achieves transplantation 
purposes
Zero risk to the donor Positive utilisation of CBU
Less stringent HLA 
matching requirements 
with easy access to rare 
haplotypes
Transplant possible for 
many recipients 
Legend: CBU = cord blood unit; GVHD = graft-versus-host disease; 
GVL = graft-versus-leukaemia; HLA = human lymphocyte antigen
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tests could be improved by taking a detailed family 
history from the parents. 
Despite all of the above difficulties, CBT is 
growing, and CBU storage is rising worldwide. 
The increasing interest in CBU has therefore 
necessitated the need for CBBs of which there are 
currently two types. 
National Voluntary Cord 
Blood Banks
National voluntary CBBs generally cater for 
mothers who have children with a disease that is 
cured by bone marrow transplant (BMT) such 
as thalassaemia, sickle cell disease or leukaemia. 
In these cases, mothers are encouraged to collect 
their babies' CB for possible future related umbilical 
CBT. These CBUs are collected and a process of 
HLA matching is done. It is also now possible in 
some centres to make a selection of disease-free 
offspring and HLA-matched babies as part of 
preimplantation genetic determination (PGD).12
Parents also can elect to donate the CBU of their 
baby to the national CBB to be used for patients 
where donors could not be found from their own 
family, allowing many matched but unrelated 
CBTs to be performed. With the average family 
size declining in the Western world, it is estimated 
that only about 25% of Caucasians will have a fully 
matched unrelated donor, and CBT has become 
in this regard an attractive source of stem cells.13 
Recent statistics suggest that more than 400,000 
CBU units are stored in banks in about 40 countries 
worldwide for use in unrelated transplants; of these, 
around 20,000 CBUs have been used for transplant 
so far worldwide, contributing to the cure of many 
children with haematological malignancies and 
bone marrow failure disorders who do not have 
matched family donors.14 Interestingly in fact, CBT 
has become more popular, particularly in children, 
and in 2009 more unrelated CBTs were performed 
than unrelated BMTs worldwide.15,13 Public banks 
store CBUs free of charge, samples are used to treat 
any patient without a donor and these banks are 
financed by public money.16
probably the most important limitation in CBT.9 
Furthermore, since these units are small, (with 
reduced volume and quantity of stem cells), they 
may not be sufficient for large patients, although 
this could be augmented by using two human 
lymphocyte antigen (HLA) matched units at the 
same time. Efforts are being made to enhance the 
number, potency and engrafting capabilities of the 
collected stem cells through ex-vivo and in vivo 
manoeuvres, by modulating the microenvironment, 
cell receptors, and signalling pathways that control 
them.2
There are also efforts to enhance engraftment, 
including enhancing homing of the transfused cells 
as well as direct intra-bone marrow injections.10,11 
The stored unit is not known for any severe 
haematologic or immune disorders, which may be 
transferred by the transplant process, and only for 
this reason, the donor is examined carefully after 6 
months and the unit is also tested for haematologic 
and immune deficiency syndromes which may 
manifest only in the adult life. Extensive testing 
for common hereditary disorders, although very 
relevant to a country such as Oman, would be 
quite expensive, and the predictive value of such 
Table 2: Disadvantages of cord blood transplantation
Disadvantages Consequences 
Reduced cell dose May delay engraftment/
reduce survival
Units may be small Large adult recipients (>60 
Kg) require two units 
Haematologic and 
immunologic disorders may 
not be apparent at birth
Requires careful donor 
screening and testing for 
common hereditary blood 







Figure 1: Indications for bone marrow transplantation, 
Sultan Qaboos University Hospital, Oman, June 1995 
to Oct 2010.
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Private Cord Blood 
Banking
Upon requests from interested parents, CBUs are 
also collected for personal use of that newborn in 
the future and, although the odds ratio for their 
utilisation has risen with time, it remains between 
1 in 25,000 to 1 in 200,000 in the first 20 years of 
life.17 This has resulted in the proliferation of private 
(for-profit) CBBs that store these units. Their 
number is rising worldwide, capitalising on the 
idea that CB usage is expanding daily, beyond the 
currently available indications. These banks charge 
a fee to store CBUs exclusively for that neonate’s 
family only and only this family may access them. 
There are about 900,000 CBUs stored in private 
banks and more than 100 reports of successful 
autologous CBTs done worldwide by this method. 
Although the use of such CBUs for non-malignant 
conditions is reasonable, their use for the treatment 
of malignant conditions such as leukaemia will 
be limited by the lack of GVL—one of the main 
reasons for having allogeneic transplants. Caution 
has to be exercised in unrestrictedly advocating 
the widespread use of such banks, one of the many 
reasons being the limited future clinical utility of 
CBUs; for example, the European Group for Blood 
and Marrow Transplantation (EMBT) reported 544 
cord blood transplants in 2006, but none of them 
was autologous.18 
Furthermore, the professional reluctance to 
accept private CBBs stems from the fact that the 
amount of total nucleated cells (TNC) in these 
units is small allowing at most only paediatric 
transplants. It is also possible that these CBUs are 
contaminated with leukaemogenic cells prohibiting 
the most important indications for cord transplant 
in childhood leukaemia.19 The yield of CBUs as 
well as their utilisation for mesenchymal stem cell 
therapy remains controversial.20 Arguments for 
lack of support for private (for profit) banks from 
academic and scientific community,  rest on the 
lack of clinical justifications for autologous banking, 
poor quality standards regarding collection and 
storage, no guarantees in case of bankruptcy and 
misleading advertising from CB companies.20 
Recent studies from European countries suggest 
a strong preference for public CBB as opposed to 
private blood banking.16,21 Hybrid banks are also 
gaining popularity, where companies are collecting 
units for a fee for a private family use, and at the 
same time collect units for national use. This enables 
local health authorities to cover some of the costs of 
storing these public units.19
What are the Indications 
for Cord Blood 
Transplantation?
CBUs contain a large number of stem cells that could 
be used in transplanting many diseases including 
Sickle cell anaemia: 8
Blackfan Diamond syndrome: 1
Glanzmanns thrombasthaenia: 2
Fanconi’s anaemia: 5







MHC Class II deficiency: 2
Chediak Higashi syndrome: 1
Congenital neutropaenia: 1
Interferon gamma receptor deficiency: 2Thalassaemia major: 47
Primary immunodeficiency
Figure 2: Bone marrow transplantation for hereditary blood disorders at Sultan Qaboos University Hospital, Oman, 
June 1995 to Oct 2010.
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response. However, more recently we have started 
reduced intensity conditioning transplantations 
(RIC) allowing us to include older patients with 
malignant conditions as  well as more complicated 
patients with non-malignant disease such as SCD 
patients. RIC, particularly in SCD, has been used 
following the understanding of improved survival 
of healthy donor erythrocytes as compared to the 
recipient abnormal cells. Furthermore,  as ineffective 
erythropoiesis lends a competitive advantage to 
donor erythroid progenitors, this creates a mixed 
donor/recipient chimera to co-habilitate together 
first. Later the donor clone eventually dominates 
and replaces the recipient’s original clone. RIC has 
also allowed many patients who could not tolerate 
a fully myeloablative therapy to have a stem cell 
transplant, allowing appropriate disease control 
with acceptable transplant related morbidity/
mortality.27
The spectrum of the conditions that we have 
treated in our centre is shown in Figure 1, whereas 
Figure 2 outlines in detail the transplantations 
for hereditary blood disorders and is reflective of 
pattern of diseases that are prevalent in Oman. Our 
CBB was established as the first national CBB in 
the country to cater for parents who have a child 
suffering from one of the disorders that are cured by 
BMT and who wanted their newborn baby’s CBU 
to be collected and processed for possible matched 
related transplant for their offspring. We have also 
created a voluntary CB banking system for those 
who want to donate their baby’s CB to our national 
CBB. Having obtained local ethical approval, our 
counsellors approach expectant mothers and their 
partners in the antenatal clinic for consent to 
collect cord blood. This is then collected by trained 
midwifes in the delivery ward, and undergoes red 
cell depletion at our stem cell processing laboratory. 
Samples are taken for HLA typing, serology for 
hepatitis and HIV as well as microbial cultures. Also 
the sample undergoes cell counts and, in related 
(sibling) cord samples, any count is acceptable; 
however, in voluntary cord blood samples, only 
units with total nucleated cells above 6 x 108/kg are 
cryopreserved, other units being discarded.28 So far 
we have collected cord blood from 81 siblings and 
>40 unrelated CB units. The number of the frozen 
CBUs is increasing and our aim is to establish a 
fully fledged CBB according to the international 
regulations of the Foundation for Accreditation 
acute and chronic leukaemia, other malignancies 
such as lymphoma, hereditary blood disorders 
such as sickle cell disease (SCD), thalassaemia and 
many bone marrow failure syndromes as well as 
immune deficiency states. The reports of disease 
free survival in various conditions range from 
40–80% in paediatric unrelated transplants and 
20–57% in adults transplants with varying times 
of follow-up.12,22-24 According to the most recent 
data from multicentre registries, there are several 
factors that determine the outcome of transplants 
including the cell dose, age, gender, CMV status and 
stage of the disease at the time of the transplant.24-25 
In the presence of in vitro expansion, there may be a 
role for CB in the treatment of degenerative diseases 
such as cardiac, neurological and rheumatic diseases 
in what is known as cellular regenerative therapy, 
an argument used by the advocates for private CBB 
groups.26  
Umbilical Cord Blood 
Banking and Stem Cell 
Transplantation in Oman
Stem cell transplantation (bone marrow [BM], 
peripheral blood [PB] and CB), has been carried out 
at Sultan Qaboos University Hospital since 1995. 
Although the start was modest in terms of numbers, 
over the years more has been achieved, and results 
are now comparable with the best transplant 
centres worldwide. Currently, having done over 
200 transplants of BM, PB, and CBT for leukaemia, 
myeloma, lymphoma, hereditary blood disorders 
and immune deficiency syndromes, the programme 
is gaining strength. Diversification was achieved in 
the programme by the use of BM, PB, and CB both 
in related and, more recently, unrelated donors, as 
well autologous transplantations. The programme 
aims to address the unique disease distributions 
seen in our country by catering for transplants in 
haemoglobin disorders such as thalassaemia and 
sickle cell disease, as well as immune deficiency 
syndromes, and malignant disorders such as 
leukaemia, lymphoma and myeloma. Furthermore, 
for successful stem cell transplantation, 
traditionally a full myeloablative conditioning 
therapy using chemotherapy, radiotherapy or both 
has been used. This helps to create a less hostile 
BM environment, eradicates any residual abnormal 
clone and suppresses the recipient’s immune 
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obese-diabetic/severe combined immunodeficiency 
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transplantation in patients with thalassaemia and 
sickle cell disease. Blood 2003; 101:2137–43.
13. Rocha V. Lacatelli F. Searching for alternative 
hematopoietic stem cell donors for pediatric patients. 
Bone Marrow Transplantat 2008; 41:207–14.
14. Ballen K. Challenges in umbilical cord blood stem 
cell banking for stem cell reviewers and reports. 
Stem Cell Rev 2010; 6:8–14.
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epilogue. Semin Hematol 2010; 47:97–103.
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Platz A, Rebulla P, et al. Banking cord blood stem 
cells: attitude and knowledge of pregnant women 
in five European countries. Transfusion 2011; 
51:578–86. 
17. Ballen K, Barker JN, Stewart SK, Greene MF, Lane 
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personal use. Biol Blood Marrow Transplant 2008; 
14:356–63.
18. Gratwohl A, Baldomero H, Frauendorfer 
K, Rocha V, Apperley J, Niederwieser D. 
The EMBT activity survey 2006 on 
haematopoietic stem cells transplantation: 
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Bone Marrow Transplant 2008; 41:687–705.
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blood banking. BMJ 2008; 336:642–4.
20. Fisk NM, Roberts IA, Markwald R, Mironov V. 
Can routine commercial cord blood banking 
be scientifically and ethically justified? PloS Med 
2005; 2:e44.
21. Edozien LC. NHS maternity units should not 
encourage commercial banking of umbilical cord 
blood. BMJ 2006; 333:801–4. 
22. Kurtzberg J, Laughlin M, Graham ML, Smith C, 
Olson JF, Halperin EC, et al. Placental blood as a 
source of hematopoetic stem cells for transplantation 
into unrelated recipients. New Engl J Med 1996; 
335:157–66.
23. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri 
DA, Wagner JE, et al. Hematopeitic engraftment 
and survival in adult recipients of umbilical-cord 
blood from unrelated donors. N Engl J Med 2001; 
344:1815–22.
24. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, 
on Cell Therapy (FACT). This foundation edits 
the NETCORD-FACT international standards 
for CB collection, processing, testing and banking 
selection.29
Conclusion 
Stem cells derived from CB, BM, and PB are 
contributing significantly to the curative treatment 
potential available for many acquired and congenital 
disorders in Oman and worldwide. National CBBs 
remain the preferred option, on economic, scientific 
and ethical grounds, until there are further advances 
in knowledge on the use of autologous CBT. Our 
strategy is to make stem cell therapy accessible to 
our patients, employing well established procedures 
for stem cell collection, storage, in vitro expansion 
and manipulation in order to achieve a successful 
national, culturally accepted CBB.
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